Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 42 articles:
HTML format
Text format



Single Articles


    May 2017
  1. KEATING JJ, Runge JJ, Singhal S, Nims S, et al
    Intraoperative near-infrared fluorescence imaging targeting folate receptors identifies lung cancer in a large-animal model.
    Cancer. 2017;123:1051-1060.
    PubMed     Text format     Abstract available


  2. MINO-KENUDSON M
    Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.
    Cancer. 2017 May 4. doi: 10.1002/cncy.21873.
    PubMed     Text format    


  3. TARHINI AA, Rafique I, Floros T, Tran P, et al
    Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30717.
    PubMed     Text format     Abstract available


  4. CHUANG JC, Neal JW
    The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30718.
    PubMed     Text format    


    April 2017
  5. ERSEK M, Miller SC, Wagner TH, Thorpe JM, et al
    Association between aggressive care and bereaved families' evaluation of end-of-life care for veterans with non-small cell lung cancer who died in Veterans Affairs facilities.
    Cancer. 2017 Apr 17. doi: 10.1002/cncr.30700.
    PubMed     Text format     Abstract available


  6. SABRA MM, Sherman EJ, Tuttle RM
    Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma.
    Cancer. 2017 Apr 3. doi: 10.1002/cncr.30690.
    PubMed     Text format     Abstract available


    March 2017
  7. ZHANG L, Jiang T, Li X, Wang Y, et al
    Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
    Cancer. 2017 Mar 27. doi: 10.1002/cncr.30677.
    PubMed     Text format     Abstract available


  8. SUN B, Brooks ED, Komaki RU, Liao Z, et al
    7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Cancer. 2017 Mar 27. doi: 10.1002/cncr.30693.
    PubMed     Text format     Abstract available


    January 2017
  9. REYNOLDS JP, Zhou Y, Jakubowski MA, Wang Z, et al
    Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples.
    Cancer. 2017 Jan 13. doi: 10.1002/cncy.21812.
    PubMed     Text format     Abstract available


  10. PRINTZ C
    FDA approves breakthrough immunotherapy for patients with non-small-cell lung cancer.
    Cancer. 2017;123:191.
    PubMed     Text format    


    December 2016
  11. BISHOP JA, French CA, Ali SZ
    Cytopathologic features of NUT midline carcinoma: A series of 26 specimens from 13 patients.
    Cancer. 2016;124:901-908.
    PubMed     Text format     Abstract available


    September 2016
  12. SANBORN RE, Patel JD, Masters GA, Jayaram N, et al
    A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.
    Cancer. 2016 Sep 1. doi: 10.1002/cncr.30287.
    PubMed     Text format     Abstract available


    August 2016
  13. LAMPSON BL, Nishino M, Dahlberg SE, Paul D, et al
    Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.
    Cancer. 2016 Aug 15. doi: 10.1002/cncr.30270.
    PubMed     Text format     Abstract available


    July 2016
  14. PETERS EN, Warren GW, Sloan JA, Marshall JR, et al
    Tobacco assessment in completed lung cancer treatment trials.
    Cancer. 2016 Jul 26. doi: 10.1002/cncr.30223.
    PubMed     Text format    


  15. MILLER JA, Kotecha R, Suh JH
    Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer.
    Cancer. 2016 Jul 8. doi: 10.1002/cncr.30188.
    PubMed     Text format    


  16. HALASZ LM, Uno H, Punglia RS
    Reply to comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer.
    Cancer. 2016 Jul 8. doi: 10.1002/cncr.30187.
    PubMed     Text format    


    June 2016
  17. LIM SH, Sun JM, Choi YL, Kim HR, et al
    Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30135.
    PubMed     Text format     Abstract available


  18. ERSEK JL, Eberth JM, McDonnell KK, Strayer SM, et al
    Knowledge of, attitudes toward, and use of low-dose computed tomography for lung cancer screening among family physicians.
    Cancer. 2016 Jun 13. doi: 10.1002/cncr.29944.
    PubMed     Text format     Abstract available


    May 2016
  19. BELANI CP, Dahlberg SE, Rudin CM, Fleisher M, et al
    Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).
    Cancer. 2016 May 10. doi: 10.1002/cncr.30062.
    PubMed     Text format     Abstract available


    April 2016
  20. HALASZ LM, Uno H, Hughes M, D'Amico T, et al
    Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer.
    Cancer. 2016 Apr 18. doi: 10.1002/cncr.30009.
    PubMed     Text format     Abstract available


  21. GONCALVES PH, Peterson SL, Vigneau FD, Shore RD, et al
    Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data.
    Cancer. 2016 Apr 8. doi: 10.1002/cncr.30000.
    PubMed     Text format     Abstract available


    March 2016
  22. OU W, Li N, Wang SY, Li J, et al
    Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).
    Cancer. 2016;122:740-7.
    PubMed     Text format     Abstract available


  23. MOR V, Joyce NR, Cote DL, Gidwani RA, et al
    The rise of concurrent care for veterans with advanced cancer at the end of life.
    Cancer. 2016;122:782-90.
    PubMed     Text format     Abstract available


    February 2016
  24. ARMSTRONG K, Kim JJ, Halm EA, Ballard RM, et al
    Using lessons from breast, cervical, and colorectal cancer screening to inform the development of lung cancer screening programs.
    Cancer. 2016 Feb 29. doi: 10.1002/cncr.29937.
    PubMed     Text format     Abstract available


  25. FUCITO LM, Czabafy S, Hendricks PS, Kotsen C, et al
    Pairing smoking-cessation services with lung cancer screening: A clinical guideline from the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco.
    Cancer. 2016 Feb 24. doi: 10.1002/cncr.29926.
    PubMed     Text format     Abstract available


  26. GUIJARRO-MUNOZ I, Roarty EB, Heymach JV
    Bevacizumab beyond disease progression for advanced non-small cell lung cancer: Does persistence have its rewards?
    Cancer. 2016 Feb 1. doi: 10.1002/cncr.29894.
    PubMed     Text format    


  27. TAKEDA M, Yamanaka T, Seto T, Hayashi H, et al
    Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
    Cancer. 2016 Feb 1. doi: 10.1002/cncr.29893.
    PubMed     Text format     Abstract available


  28. TEVAARWERK AJ, Lee JW, Terhaar A, Sesto ME, et al
    Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study.
    Cancer. 2016;122:438-46.
    PubMed     Text format     Abstract available


    January 2016
  29. LITZELMAN K, Kent EE, Rowland JH
    Social factors in informal cancer caregivers: The interrelationships among social stressors, relationship quality, and family functioning in the CanCORS data set.
    Cancer. 2016;122:278-86.
    PubMed     Text format     Abstract available



  30. Xiu-Yi Zhi, Jin-Ming Yu, and Yuan-Kai Shi. Chinese Guidelines on the Diagnosis and Treatment of Primary Lung Cancer (2015 Version). Cancer. 2015;121:3165-3181.
    Cancer. 2016;122:162.
    PubMed     Text format    


    December 2015
  31. VILLALONA-CALERO MA, Lam E, Otterson GA, Zhao W, et al
    Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.
    Cancer. 2015 Dec 28. doi: 10.1002/cncr.29856.
    PubMed     Text format     Abstract available


  32. BUNN PA JR, Gaspar LE, Weyant MJ, Mitchell JD, et al
    Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer.
    Cancer. 2015 Dec 23. doi: 10.1002/cncr.29797.
    PubMed     Text format    


  33. STEUER CE, Behera M, Berry L, Kim S, et al
    Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
    Cancer. 2015 Dec 22. doi: 10.1002/cncr.29812.
    PubMed     Text format     Abstract available


    November 2015
  34. GREM JL, Kos ME, Evande RE, Meza JL, et al
    A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
    Cancer. 2015;121:3862-8.
    PubMed     Text format     Abstract available


  35. TRAEGER L, McDonnell TM, McCarty CE, Greer JA, et al
    Nursing intervention to enhance outpatient chemotherapy symptom management: Patient-reported outcomes of a randomized controlled trial.
    Cancer. 2015;121:3905-13.
    PubMed     Text format     Abstract available


    September 2015
  36. NAIDOO J, Sima CS, Rodriguez K, Busby N, et al
    Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
    Cancer. 2015;121:3212-20.
    PubMed     Text format     Abstract available


  37. BISHOP AJ, Ensor J, Moulder SL, Shaitelman SF, et al
    Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy.
    Cancer. 2015 Sep 8. doi: 10.1002/cncr.29681.
    PubMed     Text format     Abstract available


  38. MAIN BG, McNair AG, Blazeby JM
    Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer.
    Cancer. 2015 Sep 3. doi: 10.1002/cncr.29673.
    PubMed     Text format    


  39. WINNER M, Kim Y, Pawlik TM
    Reply to patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer.
    Cancer. 2015 Sep 3. doi: 10.1002/cncr.29671.
    PubMed     Text format    


  40. CHEN ZM, Peto R, Iona A, Guo Y, et al
    Emerging tobacco-related cancer risks in China: A nationwide, prospective study of 0.5 million adults.
    Cancer. 2015;121 Suppl 17:3097-106.
    PubMed     Text format     Abstract available


  41. PASKETT ED, Bernardo BM, Khuri FR
    Tobacco and China: The worst is yet to come.
    Cancer. 2015;121 Suppl 17:3052-4.
    PubMed     Text format    


    June 2015
  42. KIM Y, Winner M, Page A, Tisnado DM, et al
    Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer.
    Cancer. 2015 Jun 19. doi: 10.1002/cncr.29530.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: